Results 171 to 180 of about 692,269 (276)

Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer. [PDF]

Oncotarget
Zanjirband M, Curtin N, Edmondson RJ, Lunec J.   +3 more
europepmc   +1 more source

Arginine methylation as a regulatory ratchet in cancer: From substrate selection to malignant‐state stabilization

Molecular Oncology, Volume 20, Issue 10, Page 2466-2489, October 2026.
Arginine methylation can be viewed as a persistence‐prone post‐translational modification regulated by a network of PRMTs. Competitive and compensatory interactions among PRMTs can redistribute methylation across substrate pools shaped by sequence, structural, spatial, and environmental layers, reinforcing RNA‐processing, chromatin, and signaling ...
So Hyun Kwon, Ji Min Lee
wiley   +1 more source

MDM2 Inhibitor AMG-232 [PDF]

, 2020
openaire   +1 more source

SPSB1 Promotes Subcutaneous Adipose Hyperplasia in Facial Port‐Wine Stains by Controlling HDAC1 Degradation and Stability Through Two Distinct Proteolytic Pathways

Advanced Science, Volume 13, Issue 57, 14 October 2026.
In PWS‐ASPCs, FOSL1 drives the expression of SPSB1. SPSB1, as part of the ESC complex, further binds to HDAC1 and promotes K29‐linked and K48‐linked polyubiquitination of HDAC1. These modifications facilitate the degradation of HDAC1 through the ALP and UPS pathways, respectively.
Hongrui Chen, Bin Sun, Yajing Qiu, Chen Hua, Xiaoxi Lin, Wei Gao   +5 more
wiley   +1 more source

MDM2 Inhibitor BI 907828 [PDF]

, 2020
openaire   +1 more source

UFL1‐Mediated UFMylation of ENO1 Restrains Aerobic Glycolysis and Colorectal Cancer Progression

Advanced Science, Volume 13, Issue 59, 23 October 2026.
UFMylation restrains aerobic glycolysis and colorectal cancer progression by modifying the glycolytic enzyme ENO1. Pharmacological enhancement of the UFL1–ENO1 interaction by the FDA‐approved antibiotic torezolid promotes ENO1 UFMylation, suppresses tumor metabolism, and sensitizes colorectal cancer to chemotherapy, revealing an actionable metabolic ...
Xiuqing Ma, Rui Wan, Yueyuan Zhong, Ziyang Cui, Xuan Zhang, Xiaoqiang He, Rong Wang, Lei Huang, Wan‐Yang Sun, Rong‐Rong He, Yang Zhou, Jianshuang Li, Li Shen, Shao‐Hua Wang, Tongzheng Liu   +14 more
wiley   +1 more source

Synergistic p53 Pathway Activation Through Sono‐Gene Therapy Induced by Ultrasound‐Triggered Theranostic Mesoporous Nanoparticles

Advanced Science, Volume 13, Issue 60, 28 October 2026.
Schematic representation of ultrasound‐mediated ICG/siCD24@MSN‐LCD from nanostructure to synergistic sono‐gene therapy. This nanoplatform targets ASGPR via the LCD shell, which dissociates to release loaded ICG and siCD24. The core mechanism involves ultrasound‐guided sonodynamic therapy by ICG and CD24 knockdown by siCD24, both activating the p53 axis
Yading Zhao, Lu Guo, Dandan Shi, Xiao Sun, Mengmeng Shang, Song Ning, Shuting Huang, Xiaoxuan Wang, Rui Liu, Yuye Fu, Suyun Li, Jie Li   +11 more
wiley   +1 more source

Fibrillarin Resists Cellular Senescence Via SIRT1‐Dependent Nicotinamide Metabolism and Its Inhibition Sensitizes Senolytic Therapy in Esophageal Squamous Cell Carcinoma

Advanced Science, Volume 13, Issue 60, 28 October 2026.
FBL directly binds to and stabilizes SIRT1 by blocking its ubiquitin‐proteasome degradation, thereby sustaining nicotinamide metabolism and redox homeostasis to counteract cellular senescence in ESCC. Genetic and pharmacological suppression of FBL sensitizes tumor cells to senolytic therapy.
Xing Jin, Hong Liu, Ling Gao, Lei Liu, Ji‐Bin Liu, Xiaoxia Jin, Ming‐Song Wang, Dan Liu, Li Feng, Wen‐Lian Chen   +9 more
wiley   +1 more source

TRIM28‐Derived Peptide Exerts Anti‐Tumor Roles by Stabilizing Tumor Suppressive BRD7 Protein in Multiple Cancers

Advanced Science, Volume 13, Issue 60, 28 October 2026.
An α‐helical peptide, TAB12, designed to mimic the TRIM28 binding interface, competitively disrupts the TRIM28‐BRD7 interaction, thereby blocking ubiquitin‐mediated degradation of the tumor suppressor BRD7. This stabilization unleashes potent anti‐tumor effects across multiple tumor types with a favorable safety profile, offering a feasible strategy ...
Qingqing Wei, Changning Xue, Mengna Li, Jianxia Wei, Lemei Zheng, Shipeng Chen, Yijie Wang, Yumei Duan, Yanwei Luo, Wei Xiong, Ming Zhou   +10 more
wiley   +1 more source

Advances in Aptamer Drug Delivery Systems for Treatment of Glioblastoma

Advanced Science, Volume 13, Issue 58, 19 October 2026.
Aptamers have remarkable recognition capacity which is suitable for assisting drug delivery for GB. This review demonstrates that aptamers have great potential as targeted therapeutic carriers, conjugated to various therapeutic carriers, using a range of conjugation strategies and chemistries.
Alexandra R. Paul, Alexandra Moreno Mitchell, Dean O'Neil, Yutong Luo, Khuloud T. Al‐Jamal   +4 more
wiley   +1 more source